25 news items
Pancreatic Cancer on the Rise: How Biotech Firms are Developing Groundbreaking Treatments
CADL
FGEN
ONCY
12 Jun 24
and atezolizumab. The main goals are to measure how well the treatments work and their safety. Additionally, the study will look at progression-free survival (how
Pancreatic Cancer on the Rise: How Biotech Firms are Developing Groundbreaking Treatments
CADL
FGEN
ONCY
12 Jun 24
. The main goals are to measure how well the treatments work and their safety. Additionally, the study will look at progression-free survival (how long
Kevzara® (sarilumab) Approved by FDA for the Treatment of Active Polyarticular Juvenile Idiopathic Arthritis (pJIA)
REGN
11 Jun 24
finding and safety study in pediatric patients with pJIA. People living with pJIA may experience joint symptoms such as pain, stiffness
Goldman Sachs Optimistic About Regenxbio's Gene Therapy Pipeline, Sees Over 160% Upside
ABBV
FDMT
REGN
7 Jun 24
to the high standards of efficacy and safety set by newer anti-VEGF treatments that require fewer injections, e.g., high dose Regeneron
What's Going On With FibroGen Stock Tuesday?
FGEN
REGN
4 Jun 24
Gal9 levels of expression. Phase 1 trials evaluating the safety and efficacy of FG-3165 in patients with select solid tumors are expected to begin
1sziy39355h4 5mp3mv
FGEN
REGN
3 Jun 24
trials evaluating the safety and efficacy of FG-3165 in patients with select solid tumors is expected to begin enrollment in the second half of 2024
v91mdxbl4v4dznx61caq397n3zf6ivv6z91t5ssuztrej13c65ftlank
REGN
SNY
31 May 24
and NOTUS phase 3 studies, which evaluated the efficacy and safety of Dupixent in adults with uncontrolled COPD and evidence of type 2
khzgnv vvy798vqu7
REGN
31 May 24
and safety of Dupixent in adults with uncontrolled COPD with evidence of type 2 inflammation (i.e., blood eosinophils ≥300 cells per μL). All patients
dkvv83ot51wovf5y980pbk qcqorphlf5g2c66r0dto8nu
REGN
31 May 24
studies that evaluated the efficacy and safety of Dupixent in adults with uncontrolled COPD with evidence of type 2 inflammation (i.e., blood
7qgdsziw3nnup2wv97w8 ruafhqd
REGN
31 May 24
. The potential use of Dupixent in COPD is currently under clinical development, and the safety and efficacy have not been fully evaluated by any regulatory
45gdpj38wv7njahv pxryrbm7
REGN
31 May 24
clinical development, and the safety and efficacy have not been fully evaluated by any regulatory authority. About the BOREAS and NOTUS
1won49sgvw
BHVN
REGN
29 May 24
toxicity, that may translate to an improved clinical efficacy and safety profile
j5a5qb
REGN
23 May 24
cutoff. Safety was assessed in 84 patients across multiple solid tumor types at a variety of doses of REGN7075. REGN7075
vbg72 cy3x5psudwxsq6xk9ay4
REGN
20 May 24
, as defined by PROs in Evaluating Respiratory Symptoms in COPD (E-RS). The safety results were generally consistent
q0pj8s pe07ckdofcua96jp8fbbi7g02ez3tujt0w565ukzhl5j0nm56362a
REGN
20 May 24
). The safety results were generally consistent with the known safety profile of Dupixent in its approved indications
gpo5g6n5qxgxtrr5su 4hffenrduk1
REGN
13 May 24
supported by the safety data of Dupixent in its currently approved indications for adolescents. Safety results in both SINUS-24 and SINUS-52 were
hy74xe0kfc55f909 iw87h4w7l1l
REGN
8 May 24
use of DB-OTO for otoferlin-related hearing loss is currently under clinical investigation, and its safety and efficacy have not been evaluated by any
7bggq320e3v2mqoxw1d3yqd05g5 vlnurh8umt1kx4sdtrxlkfws
REGN
SNY
2 May 24
in healthy volunteers intended to demonstrate the safety of a higher dose of trevogrumab has completed enrollment.
Over 400
sa5arhxacsf6k6sva179k7gawumu
REGN
2 May 24
/R FL and one for R/R DLBCL) did not identify any approvability issues with the clinical efficacy or safety, trial design, labeling, or manufacturing
erycznh5gs63oq7s44ot6wab7w54 8slolekjb2ozbgxxwgytohxhaqbrj
REGN
29 Apr 24
extensive data presentations at ARVO showcase the differentiated efficacy, safety and durability of EYLEA HD, and demonstrate our commitment to advancing